Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The seasonal SARS-CoV-2 DNA vaccine is a preclinical-stage nucleic acid vaccine candidate developed by Orlance. It is designed to provide seasonal protection against COVID-19 by expressing SARS-CoV-2 antigens in vivo to induce both systemic and mucosal immunity. The vaccine utilizes Orlance's proprietary MACH-1 epidermal gene-gun delivery system, which delivers microparticle-coated DNA directly into the skin's epidermis. This delivery method is intended to target antigen-presenting cells efficiently, potentially offering a stable, needle-free alternative to traditional liquid-based vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on seasonal SARS-CoV-2 DNA vaccine.